Keracutan

Acitretin, the active ingredient in Keracutan, is a retinoid presented as an oral tablet for oral use. It is indicated for the treatment of severe plaque psoriasis and other disorders of keratinization, helping to normalize skin cell growth in adult patients.

GNH USA supplies Keracutan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows EU‑quality standards and provides reliable global distribution for this prescription medication.

Acitretin is a systemic retinoid used in the management of disorders characterized by abnormal keratinization.

- Severe plaque psoriasis: reduces scaling and plaque thickness by normalizing keratinocyte differentiation. - Ichthyosis vulgaris: improves skin texture by decreasing epidermal hyperproliferation. - Other keratinization disorders: helps control abnormal skin cell turnover in conditions such as keratosis pilaris.

Common Side Effects: - Dry skin: increased xerosis and scaling. - Cheilitis: inflammation and cracking of the lips. - Elevated triglycerides: lipid abnormalities that may require monitoring. - Hair loss: temporary alopecia in some patients.

Serious or Rare Side Effects: - Hepatotoxicity: elevation of liver enzymes indicating potential liver injury. - Severe hyperlipidemia: marked increase in cholesterol or triglyceride levels. - Pseudotumor cerebri: intracranial hypertension presenting with headache and visual changes.

Acitretin requires careful monitoring due to its teratogenic potential and metabolic effects. - Pregnancy contraindication: teratogenic (Category X); avoid use in women of childbearing potential. - Contraception requirement: effective contraception must be maintained during treatment and for at least three years after discontinuation. - Liver function monitoring: assess hepatic enzymes before initiation and periodically during therapy. - Lipid profile monitoring: check serum triglycerides and cholesterol regularly. - Visual acuity monitoring: assess for signs of intracranial hypertension such as headaches or visual disturbances. - Store at ambient temperature: keep below 25°C, retain in the original pack, and protect from moisture.

Acitretin may interact with several drug classes, requiring avoidance or close monitoring.

Major Interactions (Avoid): - Tetracycline antibiotics: increased risk of intracranial hypertension. - Vitamin A supplements: additive teratogenicity and hypervitaminosis A. - Combined oral retinoids: heightened systemic toxicity.

Moderate Interactions (Monitor Closely): - Lipid‑lowering agents (statins): may require dose adjustment due to altered lipid levels. - Anticoagulants (warfarin): possible alteration of INR and bleeding risk. - Phototherapy: may enhance photosensitivity and skin reactions.